ADGRG1 and acute myeloid leukemia: Daga et al. subsequently showed that GPR56 is the prominent surface marker of the LSC-enriched CD34+CD38− AML cells, while Daria et al. confirmed the association of high GPR56 expression with the inferior prognosis of AMLs [88].